Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, Italiano A, Lavernia J, Vallejo A, Tos PD, Le Loarer F, Gonzalez-Campora R, Ramos R, Hernández-Jover D, Gutierrez A, Serrano C, Monteagudo M, Letón R, Robledo M, Moura DS, Martin-Ruiz M, López-Guerrero JA, Cruz J, Fernandez-Serra A, Blay JY, Fumagalli E, Martinez-Marin V. Martin-Broto J, et al. Among authors: lavernia j. Mol Cancer. 2023 Aug 9;22(1):127. doi: 10.1186/s12943-023-01832-9. Mol Cancer. 2023. PMID: 37559050 Free PMC article. Clinical Trial.
Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.
Martin-Liberal J, López-Pousa A, Martínez-Trufero J, Martín-Broto J, Cubedo R, Lavernia J, Redondo A, López-Martín JA, Mulet-Margalef N, Sanjuan X, Tirado ÒM, Garcia-Del-Muro X. Martin-Liberal J, et al. Among authors: lavernia j. Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9. Target Oncol. 2018. PMID: 29177953 Clinical Trial.
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
García Del Muro X, Maurel J, Martínez Trufero J, Lavernia J, López Pousa A, de Las Peñas R, Cubedo R, Berros JP, Casado Herráez A, de Juan A, Martín Broto J. García Del Muro X, et al. Among authors: lavernia j. Invest New Drugs. 2018 Jun;36(3):468-475. doi: 10.1007/s10637-018-0583-z. Epub 2018 Mar 12. Invest New Drugs. 2018. PMID: 29527631 Clinical Trial.
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J. Serrano C, et al. Among authors: lavernia j. Oncologist. 2019 May;24(5):680-687. doi: 10.1634/theoncologist.2018-0032. Epub 2018 Aug 20. Oncologist. 2019. PMID: 30126859 Free PMC article.
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.
Moura DS, Peña-Chilet M, Cordero Varela JA, Alvarez-Alegret R, Agra-Pujol C, Izquierdo F, Ramos R, Ortega-Medina L, Martin-Davila F, Castilla-Ramirez C, Hernandez-Leon CN, Romagosa C, Vaz Salgado MA, Lavernia J, Bagué S, Mayodormo-Aranda E, Vicioso L, Hernández Barceló JE, Rubio-Casadevall J, de Juan A, Fiaño-Valverde MC, Hindi N, Lopez-Alvarez M, Lacerenza S, Dopazo J, Gutierrez A, Alvarez R, Valverde C, Martinez-Trufero J, Martín-Broto J. Moura DS, et al. Among authors: lavernia j. Mol Oncol. 2021 Dec;15(12):3691-3705. doi: 10.1002/1878-0261.12996. Epub 2021 Jun 30. Mol Oncol. 2021. PMID: 33983674 Free PMC article.
50 results